Name: Meeting on Pre-Clinical Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research.

Place: National Institutes of Health, Neuroscience Building, 6001 Executive Blvd., Conference Room C, Bethesda, MD 20852.

Date: June 18, 2009.

Open: 8 a.m. to 8:30 a.m.

Agenda: Overview of the Cooperative Study Group for Autoimmune Disease Prevention (Prevention Centers) research program.

Closed: 8:30 a.m. to 9 a.m.

Agenda: Mid-course assessment of the Prevention Centers.

Open: 9 a.m. to 9:30 a.m.

Agenda: Overview of the

Immunobiology of Xenotransplantation Cooperative Research Program (IXCRP) research program.

Closed: 9:30 a.m. to 10:15 a.m.

Agenda: Mid-course assessment of the IXCRP.

Open: 10:30 a.m. to 11 a.m. *Agenda:* Overview of the NHP Transplantation Tolerance Cooperative Study Group (NHPCSG).

Closed: 11 a.m. to 12:15 p.m.

Agenda: Mid-course assessment of the NHPCSG; discussion of cross-cutting themes for strengthening the ongoing preclinical research portfolio.

Open: 12:30 p.m. to 1:30 p.m. *Agenda:* Discussion of future

opportunities for preclinical research. *Contact Person:* Julie Wallace, PhD,

Health Science Policy Analyst, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, 9000 Rockville Pike, Building 31, Room 9A05, Bethesda, MD 20892, (301) 496– 6623, wallaceja@niddk.nih.gov.

Please Note: The NIH has instituted security measures to ensure the safety of NIH employees and property. Upon your arrival at the Neuroscience Building, enter through the main lobby where you will be greeted at the security guard's desk. Visitors who are not NIH employees will be required to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to have their bags searched in order to enter the building. You will then be issued a visitor badge. In estimating your travel time, please allow for these security measures, particularly if you are arriving in a group. Self-parking is available for a maximum of \$8 per day.

A registration link, information about the meeting, and the agenda are available online: http:// www3.niddk.nih.gov/fund/ otherType1Diabetes09/. Dated: May 12, 2009. Sanford Garfield, Executive Secretary, DMICC, Division of Diabetes, Endocrinology and Metabolic

Diseases, NIDDK, National Institutes of Health.

[FR Doc. E9–11698 Filed 5–20–09; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Mentored Career Development, Institutional Research Training & Pathways to Independence Reviews.

Date: June 5, 2009.

Time: 11 a.m. to 12 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892. (Telephone Conference Call)

Contact Person: Charles H. Washabaugh, PhD, Scientific Review Administrator, Review Branch, NIAMS/NIH, 6701 Democracy Blvd., Room 816, Bethesda, MD 20892, 301–451–4838, washabac@mail.nih.gov.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Building Interdisciplinary Research Team (BIRT) II RFA.

Date: June 12, 2009.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892. (Virtual Meeting)

Contact Person: Charles H. Washabaugh, EP Review Branch NIAMS, One Democracy Plaza, Suite 800, MSC 4872, 6701 Democracy Plaza, Bethesda, MD 20892–4872, 301–496– 9568, *washabac@mail.nih.gov.* *Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel, Competitive Revision Reviews.

Date: June 24, 2009.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.

Contact Person: Michael L. Bloom, Ph.D., MBA, Scientific Review Administrator, EP Review Branch, NIH/NIAMS, One Democracy Plaza, Room 820, MSC 4872, 6701 Democracy Blvd., Bethesda, MD 20892– 4872, 301–594–4953, Michael Bloom@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: May 14, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–11831 Filed 5–20–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): A Creutzfeldt-Jakob Disease (CJD) Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease, Funding Opportunity Announcement (FOA) CK09–002, Initial Review

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. *Time and Date:* 12 p.m.–3 p.m., June 5,

2009 (Closed). *Place:* Teleconference.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Maîters to be Discussed: The meeting will include the initial review, discussion, and evaluation of "A Creutzfeldt-Jakob Disease Lookback Study: Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt-Jakob Disease, FOA CK09–002."

Contact Person for More Information: Wendy Carr, Ph.D., CDC, 1600 Clifton Road, NE., Mailstop D60, Atlanta, GA 30333, Telephone: (404) 498–2276.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: May 15, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–11905 Filed 5–20–09; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Arthritis and Musculoskeletal and Skin Diseases Advisory Council.

Date: June 2, 2009.

Open: 8 a.m. to 12 p.m.

Agenda: To discuss administrative details relating to the Council's business and special Reports.

Place: National Institutes of Health,

Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892.

Closed: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant

applications. *Place:* National Institutes of Health,

Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892.

Contact Person: Susana Serrate-Sztein, MD, Director, Division of Skin and Rheumatic Diseases, NIAMS/NIH, 6701 Democracy Blvd., Suite 800, Bethesda, MD 20892–4872. (301) 594–5032. szteins@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: May 14, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–11830 Filed 5–20–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel VMD–ARRA Competive Revision Applications

Date: May 29, 2009.

Time: 11 a.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree Hotel Washington, DC, 1515 Rhode Island Avenue, NW., Washington, DC 20005.

Contact Person: Jian, Wang, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4095D, MSC 7812, Bethesda, MD 20892, (301) 435–2778, *wangjia@csr.nih.gov.*

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Drug Discover ARRA CR.

Date: May 29, 2009.

Time: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Mayflower Park Hotel, 405 Olive Way, Seattle, WA 98101.

Contact Person: Hungyi Shau, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6186, MSC 7804, Bethesda, MD 20892, 301–435– 1720, *shauhung@csr.nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Special Emphasis Panel for KNOD Revision Applications.

Date: June 2, 2009.

Time: 3 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: New Orleans Marriott at the Convention Center, 859 Convention Center Boulevard, New Orleans, LA 70130. *Contact Person:* Fungai F. Chanetsa, MPH, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3135,

MSC 7770, Bethesda, MD 20892, 301–435– 1262, *chanetsaf@csr.nih.gov*. This notice is being published less than 15

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Epidemiology of Cancer Revision

Applications.

Date: June 3, 2009.

Time: 9 a.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, VA 22314.

Contact Person: Denise Wiesch, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3150, MSC 7770, Bethesda, MD 20892, (301) 435– 0684, wieschd@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Lung Toxicology ARRA CR.

Date: June 3, 2009. *Time:* 11 a.m. to l p.m.

Agenda: To review and evaluate grant

applications.

Place: Warwick Seattle Hotel, 401 Lenora Street, Seattle, WA 98121.

Contact Person: Ghenima Dirami, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4112,